TWO · 6934.TWO
Hcmed
NT$155.00NT$0.00 (0.0%)
Hcmed’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
Loading market information…
TWO · 6846.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:23 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Greenyn Biotechnology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 25.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Greenyn Biotechnology Co., Ltd’s forward annual dividend is NT$3.60 per share, paid annual. The forward yield is 6.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Greenyn Biotechnology Co., Ltd’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Greenyn Biotechnology Co., Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ingredients. These feature notable components such as Insumate, derived from bitter melon extract; Antromax, which utilizes antrodia cinnamomea; and the Zymologist 101 Phyto fermented drink. Beyond individual ingredients, Greenyn provides an extensive selection of functional product series catering to a diverse array of health and wellness needs. These encompass solutions for youth and beauty, digestive and brain health, overall body regulation, throat care, hair care, vision support, and various lifestyle enhancement formulas. Additional ranges include joint health, general nutritional and energy supplementation, immune modulation, low-burden options, sleep assistance, body contouring, circulatory support, specific formulas for men's vitality and women's intimate health, and dedicated products for mature women. Moreover, the company extends its expertise through various services, including custom product development, Original Design Manufacturing (ODM), dosage form optimization, and application support. Established in 2012, the firm's operations are headquartered in Taichung, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Mar 10, 2025 | NT$1.84+22.67% vs estimate | NT$246.16M+4.3% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | NT$1.08+1.89% vs estimate | NT$209.80M+0.86% vs estimate |
|---|
| Q1 2024 | Jun 30, 2024 | NT$0.92 | NT$191.13M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$155.00NT$0.00 (0.0%)
Hcmed’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
NT$32.30-NT$1.10 (-3.29%)
Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.82% below the high.
NT$29.45NT$0.00 (0.0%)
Genomics BioSci & Tech. Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.08% below the high.
NT$55.70+NT$0.80 (+1.46%)
TSH Biopharm Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
NT$72.10-NT$0.40 (-0.55%)
Crystalvue Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.45% below the high.
NT$28.50-NT$0.15 (-0.52%)
Chi Sheng Pharma & Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 7.92% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
